Age does not impair the efficacy of immunochemotherapy in patients with metastatic renal carcinoma

Our results demonstrated that patient age and related IL-2 dose reduction do not impair the efficacy of sc-IL-2 plus sc-INF-2a based outpatient immunochemotherapy in metastastic renal carcinoma.